Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.52 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.48 |
| ▸ | TNKS | O95271 | 3/20 | 0.48 |
| ▸ | PARP1 | P09874 | 3/20 | 0.48 |
| ▸ | TNKS2 | Q9H2K2 | 3/20 | 0.48 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.48 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.47 |
| ▸ | PRKACA | P17612 | 5/20 | 0.47 |
| ▸ | PRKACG | P22612 | 4/20 | 0.47 |
| ▸ | PRKACB | P22694 | 4/20 | 0.47 |
| ▸ | TAF1 | P21675 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.41 |
| ▸ | PRKG1 | Q13976 | 1/20 | 0.41 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.41 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.41 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29874886 | 0.81 | ZAP70 (0.52) | BRD9ZAP70TNKSPARP1TNKS2 | |
| SCHEMBL29440634 | 0.77 | IP6K1 (0.60) | BRD9TNKSPARP1TNKS2EGFR | |
| SCHEMBL15586753 | 0.76 | ROCK1 (0.51) | PARP1ROCK2PRKACAPRKACGPRKACB | |
| Hydrochloric Acid SCHEMBL31529629 | 0.76 | IP6K1 (0.58) | BRD9TNKSPARP1TNKS2EGFR | |
| SCHEMBL4005932 | 0.73 | ROCK1 (0.70) | ZAP70PARP1ROCK2PRKACAPRKCD | |
| SCHEMBL4006198 | 0.72 | ROCK2 (0.68) | ROCK2ROCK1 | |
| SCHEMBL25290996 | 0.72 | GRM5 (0.59) | PARP1TNKS2ROCK2PRKACAPRKACG | |
| SCHEMBL17755606 | 0.72 | BRD9 (0.69) | BRD9ZAP70TNKSPARP1TNKS2 | |
| SCHEMBL20443487 | 0.70 | HTR3A (0.50) | TNKSPARP1TNKS2ROCK2EGFR | |
| SCHEMBL6226394 | 0.70 | CHEK1 (0.50) | PARP1ROCK2PRKACAPRKACGPRKACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250340535-A1 | ALLOSTERIC EGFR INHIBITORS AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-11-06 | — | — | US | disclosed |
| US-20250340534-A1 | ALLOSTERIC EGFR INHIBITORS AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-11-06 | — | — | US | disclosed |
| US-12391671-B2 | Allosteric EGFR inhibitors and methods of use thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-08-19 | — | — | US | disclosed |
| CN-120004861-A | Allosteric EGFR inhibitors and methods of use thereof | 达纳-法伯癌症研究所股份有限公司 | 2025-05-16 | — | — | CN | disclosed |
| US-20220411404-A1 | ALLOSTERIC EGFR INHIBITORS AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-12-29 | — | — | US | disclosed |
| EP-4058015-A1 | ALLOSTERIC EGFR INHIBITORS AND METHODS OF USE THEREOF | Dana-Farber Cancer Institute, Inc. (US) | 2022-09-21 | — | — | EP | disclosed |
| CN-115066240-A | Allosteric EGFR inhibitors and methods of use thereof | 达纳-法伯癌症研究所股份有限公司 | 2022-09-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250340535-A1 | ALLOSTERIC EGFR INHIBITORS AND METHODS OF USE THEREOF | EGFR, ERBB2, ERBB3 | BRD9 2311/4885ZAP70 474/4885TNKS 1022/4885 |
| US-12391671-B2 | Allosteric EGFR inhibitors and methods of use thereof | EGFR, ERBB2, ERBB3 | BRD9 2311/4885ZAP70 474/4885TNKS 1022/4885 |
| US-20220411404-A1 | ALLOSTERIC EGFR INHIBITORS AND METHODS OF USE THEREOF | EGFR, ERBB2, ERBB3 | BRD9 2311/4885ZAP70 474/4885TNKS 1022/4885 |
| US-20250340534-A1 | ALLOSTERIC EGFR INHIBITORS AND METHODS OF USE THEREOF | EGFR, ERBB2, ERBB3 | BRD9 2311/4885ZAP70 474/4885TNKS 1022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.